|Founded||November 26, 1998|
|Headquarters||20 Zhichun Road, Haidian District, |
|China, exported worldwide|
|Liu Jingzhen (Chairman & Party Committee Secretary)|
|Revenue||CN¥247.110 billion (2014)|
|CN¥8.758 billion (2014)|
|CN¥2.705 billion (2014)|
|Total assets||CN¥199.192 billion (2014)|
|Total equity||CN¥31.944 billion (2014)|
|Owner||Chinese central government (100%)|
|Parent||SASAC of the State Council|
|short Chinese name|
|Footnotes / references|
in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.). Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai) and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.
China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) was founded on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).
Sinopharm BBIBP-CorV, also known as the Sinopharm COVID-19 vaccine, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19.
Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group). In December 2020, the UAE previously announced interim results showing 86% efficacy. While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.
BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia, Africa, South America, and Europe. Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021. On 7 May 2021, the World Health Organization approved the vaccine for emergency use and Sinopharm later signed purchase agreements for 170 million doses from COVAX.
The other inactivated virus COVID-19 vaccine developed by Sinopharm is WIBP-CorV.
- "中国医药集团有限公司主要领导调整" (in Chinese). Sinopharm.
- "Liu Jingzhen". Bloomberg.
- "中国医药集团总公司2016年度第一期超短期融资券发行披露材料" [Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm]. Sinopharm (in Chinese). Shanghai Clearing House. 19 January 2016. Retrieved 22 November 2016.
- "2015 Annual Report" (PDF). China Traditional Chinese Medicine. Hong Kong Stock Exchange. 28 April 2016. Retrieved 22 November 2016.
- "央企名录 (List of Central SOEs)". Official website of SASAC (in Chinese). Retrieved 3 March 2016.
- "Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal". South China Morning Post. 23 July 2018. Retrieved 29 November 2018.
- How the Sinopharm Vaccine Works Jonathan Corum and Carl Zimmer 22 March 2021, www.nytimes.com, accessed 11 April 2021
- Reuters Staff (2020-11-19). "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. Retrieved 2020-12-09.
- Corum, Jonathan; Zimmer, Carl (2021-04-26). "How the Sinopharm Vaccine Works". The New York Times. ISSN 0362-4331. Retrieved 2021-04-29.
- Kaabi, Nawal Al; Zhang, Yuntao; Xia, Shengli; et al. (May 26, 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
- "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. Retrieved 2020-12-13.
- "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020-12-09. Retrieved 2020-12-09.
- Liu R (2020-12-31). "China gives its first COVID-19 vaccine approval to Sinopharm". Reuters. Retrieved 2020-12-31.
- Turak, Natasha (2021-01-18). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 2021-01-21.
- Dawn.com (2021-02-02). "PM Imran kicks off Pakistan's Covid-19 vaccination drive". DAWN.COM. Retrieved 2021-02-03.
- Reuters Staff (2021-01-24). "Sisi says Egypt to begin COVID-19 vaccinations on Sunday". Reuters. Retrieved 2021-01-24.
- Dumpis, Toms (2021-01-27). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 2021-01-28.
- "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 2021-02-18. Retrieved 2021-02-20.
- "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. Retrieved 2021-03-26.
- Aquino, Marco (2021-02-10). "'The best shield': Peru launches inoculation drive with Sinopharm vaccine". Reuters. Retrieved 2021-02-10.
- "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 2021-02-28.
- "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". RadioFreeEurope/RadioLiberty. Retrieved 2021-01-21.
- "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 2021-02-24. Retrieved 2021-02-26.
- "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 2021-03-15. Retrieved 2021-03-16.
- "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 2021-02-05. Retrieved 2021-02-28.
- Taylor, Adam (7 May 2021). "WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine". The Washington Post. Retrieved 7 May 2021.
- "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 2021-07-12. Retrieved 2021-07-13.